<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03078725</url>
  </required_header>
  <id_info>
    <org_study_id>HSC-MS-16-1052</org_study_id>
    <nct_id>NCT03078725</nct_id>
  </id_info>
  <brief_title>Failure Rate of GLyburide And Metformin Among Gestational Diabetics</brief_title>
  <acronym>GLAM</acronym>
  <official_title>Failure Rate of GLyburide And Metformin Among Gestational Diabetics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A pragmatic, comparative effectiveness trial of glyburide versus metformin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with gestational diabetes requiring pharmaceutical treatment will be randomized to
      receive glyburide or metformin. Dose increases will be determined by the patient's physician.
      Patients will be determined to have failed either medication if glucose control can not be
      achieved with the maximum dose of the medication, if insulin is stared to achieve glucose
      control or if another oral agent is started along for glucose control.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Research was competing with other projects in the department, and no patients were recruited.
  </why_stopped>
  <start_date type="Anticipated">June 20, 2017</start_date>
  <completion_date type="Anticipated">May 10, 2018</completion_date>
  <primary_completion_date type="Anticipated">March 10, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>patients will be randomized to two groups, one receiving glyburide and one receiving metformin.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Failure rate</measure>
    <time_frame>from onset of oral therapy until delivery</time_frame>
    <description>need to start insulin therapy or another hypoglycemic agent during the pregnancy to maintain normal glucose levels or need for delivery due to hyperglycemia.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean overall plasma glucose</measure>
    <time_frame>from enrollment to delivery</time_frame>
    <description>average of all postprandial glucose measurements</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean weekly fasting glucose</measure>
    <time_frame>from enrollment to delivery</time_frame>
    <description>average of all fasting glucose measurements</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>preeclampsia</measure>
    <time_frame>from enrollment to delivery</time_frame>
    <description>preeclampsia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cesarean section</measure>
    <time_frame>from enrollment to delivery</time_frame>
    <description>mode of delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>neonatal hypoglycemia</measure>
    <time_frame>from enrollment to delivery</time_frame>
    <description>neonatal hypoglycemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LGA infant</measure>
    <time_frame>from enrollment to delivery</time_frame>
    <description>LGA infant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>birthweight &gt; 4500 grams</measure>
    <time_frame>from enrollment to deliveryfrom enrollment to delivery</time_frame>
    <description>birthweight &gt; 4500 grams</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>gestational age at birth</measure>
    <time_frame>from enrollment to delivery</time_frame>
    <description>gestational age at birth</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of medication side effects</measure>
    <time_frame>from enrollment to delivery</time_frame>
    <description>nausea, emesis, diarrhea, abdomainal bloating</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Gestational Diabetes Mellitus, Class A2</condition>
  <arm_group>
    <arm_group_label>Glyburide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>hypoglycemic agent approved for treatment of GDMA2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>hypoglycemic agent approved for treatment of GDMA2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glyburide</intervention_name>
    <description>oral hypoglycemic agent</description>
    <arm_group_label>Glyburide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>oral hypoglycemic agent</description>
    <arm_group_label>Metformin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        We will include women between 20 and 34 weeks gestational age, with a diagnosis of GDM as
        per the following criteria:

          -  1 hour Glucose tolerance test of &gt;130 mg/dl, followed by two abnormal values on 3 hour
             Glucose tolerance test, or:

          -  A single 1 hour Glucose tolerance test value of &gt; 200 mg/dl, and:

          -  Failure to achieve glycemic control with diet and exercise or deemed to require
             pharmacological therapy as per physician's criteria

        Exclusion Criteria:

          -  - Known renal impairment.

          -  Known hepatic disease.

          -  Pre-gestational diabetes.

          -  Known allergy to glyburide, metformin or sulfa drugs.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 7, 2017</study_first_submitted>
  <study_first_submitted_qc>March 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 13, 2017</study_first_posted>
  <last_update_submitted>May 1, 2018</last_update_submitted>
  <last_update_submitted_qc>May 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Jenifer Dinis Ballestas</investigator_full_name>
    <investigator_title>Medical Doctor</investigator_title>
  </responsible_party>
  <keyword>gestational diabetes</keyword>
  <keyword>glyburide</keyword>
  <keyword>metformin</keyword>
  <keyword>failure rate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes, Gestational</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Hypoglycemic Agents</mesh_term>
    <mesh_term>Glyburide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

